Pfizer says COVID-19 vaccine 90% effective in Phase 3 trial
Pfizer and BioNTech have already announced last monday, November 9, that the vaccine they jointly developed had received 90% effectivity rate against COVID-19 infection in thr ongoing phase 3 trials they have conducted.
According to Pfizer chairman and CEO Albert Bourla:
“The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19.We are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We are reaching this critical milestone in our vaccine development program at a time when the world needs it most.”
The Phase 3 or the final stage of the trial of the new vaccine, BNT162b2, began in late July and has enrolled 43,538 participants to date, 90% of whom have received a second dose of the vaccine candidate as of November 8. Moreover, Pfizer said it is gathering two months of safety data following the final dose – a requirement of the US Food and Drug Administration – to qualify for Emergency Use Authorization, which it expects by the third week in November.
“We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks,” Bourla added.